REC-2282
Small molecule
Evidence outlook · program status
Discontinued (2025-05), after a negative readout
Recursion discontinued the Phase 2/3 study in NF2-associated meningioma (Q1 2025 update, 5 May 2025): the Phase 2 passed futility only in the 40 mg cohort, the 60 mg and combined arms did not, and tumour shrinkage and clinical activity were limited across all arms. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
POPLAR-NF2 NCT05130866 · Meningioma Result from Recursion's quarterly release filed with the SEC (Form 8-K Exhibit 99.1, 5 May 2025); no registry results are posted. The release reports a futility analysis, which is not a test of either registered primary endpoint. The study was terminated by sponsor decision and the programme was discontinued. Registry: NCT05130866 | 2/3 | Cohort A: Number of Participants with Progression-free survival (PFS) at 6 Months; Cohort B: Number of Participants with PFS up to 3 years 2025-08-18 | Cohort A (Phase 2 part, PFS at 6 months): the futility threshold was passed, driven mainly by the 40 mg cohort; the 60 mg and combined dose arms did not pass the futility criteria, and tumour shrinkage was limited across all arms. No Cohort B (randomized, placebo-controlled) result has been reported. No figures released (Recursion release, 5 May 2025). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other HDAC drugs
Givinostat, Romidepsin, Vorinostat, Panobinostat, Chidamide and 1 more. Compare all 7 HDAC drugs
6 other tracked programmes target this mechanism, 6 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| REC-2282: this drug | Discontinued | Small molecule | HDAC | not yet graded | No reviewed efficacy summary | |
| Givinostat | Approved(overall) | Small molecule | HDAC | Reliable signal | NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058) | |
| Romidepsin | Approved(overall) | Small molecule | HDAC | not yet graded | No reviewed efficacy summary | |
| Vorinostat | Approved(overall) | Small molecule | HDAC | not yet graded | No reviewed efficacy summary | |
| Panobinostat | US approval withdrawn(overall) | Small molecule | HDAC | Partial signal | NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014) | |
| Chidamide | Phase 3(overall) | Small molecule | HDAC | Reliable signal | NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336 NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed | |
| Purinostat Mesylate | Phase 3(overall) | Small molecule | HDAC | not yet graded | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.